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   ABSTRACT   
  Objectives      To investigate a shared genetic aetiology for 
skin involvement in psoriasis and psoriatic arthritis (PsA) 
by genotyping single-nucleotide polymorphisms (SNPs), 
reported to be associated in genome-wide association 
studies of psoriasis, in patients with PsA.   
  Methods      SNPs with reported evidence for association 
with psoriasis were genotyped in a PsA case and control 
collection from the UK and Ireland. Genotype and allele 
frequencies were compared between PsA cases and 
controls using the Armitage test for trend.   
  Results      Seven SNPs mapping to the IL1RN, TNIP1, 
TNFAIP3, TSC1, IL23A, SMARCA4 and RNF114 genes 
were successfully genotyped. The IL23A and TNIP1 
genes showed convincing evidence for association 
(rs2066808, p = 9.1 x 10–7; rs17728338, p = 3.5 x 
10–5, respectively) whilst SNPs mapping to the TNFAIP3, 
TSC1 and RNF114 genes showed nominal evidence for 
association (rs610604, p = 0.03; rs1076160, p = 0.03; 
rs495337, p = 0.0025). No evidence for association 
with IL1RN or SMARCA4 was found but the power to 
detect association was low.   
  Conclusions      SNPs mapping to previously reported 
psoriasis loci show evidence for association to PSA, 
thus supporting the hypothesis that the genetic 
aetiology of skin involvement is the same in both PsA 
and  psoriasis.      
  Psoriatic arthritis (PsA) and psoriasis are both com-
plex diseases with genetic and environmental con-
tributions to their aetiology. Estimates suggest that 
the genetic contribution to PsA may be higher than 
psoriasis yet most work has been done on the latter 
given its greater population prevalence.  1   
  Both diseases are characterised by psoriasis skin 
involvement; if the psoriasis is aetiologically iden-
tical, then all conﬁ   rmed psoriasis susceptibility 
loci should also be associated with PsA. Of the 
psoriasis susceptibility loci studied to date, the 
  HLA Cw*0602   allele and variants mapping to the 
  IL23R   and   IL12B   genes have been associated with 
PsA.  2    –    4   It might be postulated that additional PsA 
susceptibility loci exist. This is supported by evi-
dence that the   IL13   gene locus is associated with 
PsA, but not psoriasis alone.  5     6   Furthermore, the 
recently identiﬁ  ed    TRAF3IP2   gene locus shows 
stronger effect sizes in some,  7     8   but not all,  9   PsA 
populations compared with psoriasis, suggesting 
that it too may represent a PsA-speciﬁ  c locus. If 
the skin manifestations of both diseases repre-
sent a common phenotypic endpoint arising from 
different aetiologies, some differences in suscep-
tibility loci would be expected. The identiﬁ  cation 
of risk loci speciﬁ   c to psoriasis would provide 
compelling evidence that the genetic basis of the 
skin component of the two diseases was differ-
ent. There has been some evidence reported to 
support this possibility. Variants within the   LCE   
gene locus were reported to be associated with 
psoriasis but not PsA in a German cohort,  10   but a 
subsequent study in a population from the British 
Isles showed association with PsA suggesting it is 
involved in psoriasis per se.  11   
  Genome-wide association studies (GWAS) have 
resulted in the identiﬁ  cation of further psoriasis sus-
ceptibility loci.  12     13   This provides an opportunity to 
explore further the overlap in genetic susceptibility 
between psoriasis and PsA. If the genetic   liability 
towards skin involvement is shared between 
the two diseases, then loci identiﬁ  ed in psoriasis 
GWAS would also show evidence of association of 
the susceptibility with PsA. 
  METHODS 
  Patient  samples 
  One thousand and ﬁ  fty-seven genomic DNA sam-
ples were collected from Caucasian PsA patients 
recruited from the UK and Ireland (885 UK and 
172 Ireland), the details of which have previously 
been described  14    –    16   and phenotype details are sum-
marised in supplementary table 4 (available online 
only). PsA was deﬁ   ned as the presence of both 
psoriasis and peripheral inﬂ  ammatory  arthritis 
irrespective of rheumatoid factor status. All sub-
jects provided informed consent and the study was 
approved by the North West Multicentre Research 
Ethics Committee (MREC 99/8/84).   
  Control  data 
  The data for healthy UK controls was sourced from 
the Wellcome Trust Case–Control Consortium 2 
(WTCCC2) project (  http://www.wtccc.org.uk  ). 
This project genotyped over 5000 individuals from 
the 1958 British Birth Cohort and the UK Blood 
Service Collection for the Illumina Human1M-Duo 
and the Affymetrix Human SNP Array 6.0. If con-
trol data for any single-nucleotide polymorphism 
(SNP) were not available from the WTCCC2 then 
it was generated in-house using DNA from 2104 
1958 British Birth Cohort samples. In addition, 375 
control samples were available from Ireland for 
genotyping.   
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  SNP  selection 
  Seven SNPs were selected from two published psoriasis GWAS 
available at the time of study design.  12     13   Four of the selected 
SNPs: rs17728338 (  TNIP1  ); rs2066808 (  IL23A  ); rs610604 
(  TNFAIP3  ) and rs495337 (  RNF114  ) all reached genome-wide sig-
niﬁ  cance in the reported studies. Three further SNPs: rs1076160 
(  TSC1  ); rs12983316 (  SMARCA4  ) and rs397211 (  IL1RN  ) reached 
modest levels of signiﬁ  cance.   
  Genotyping 
  Genotyping of the SNPs was performed using Sequenom’s 
MassARRAY system (San Diego, California, USA) according to 
the manufacturers’ speciﬁ  cations using 10 ng of genomic DNA 
for all PsA patients, the Ireland control samples and 1958 British 
Birth Cohort samples (where necessary).   
  Statistical  analysis 
  All quality control steps and statistical analyses were performed 
using the PLINK package.  17   SNPs and samples with greater than 
10% missing data were excluded from the study. Test statistics 
were calculated for deviation from Hardy–Weinberg equilib-
rium using an exact test, the Cochran–Armitage trend test and 
OR (including 95% CI). A p value of less than 10  −4   was consid-
ered statistically signiﬁ  cant following recommendations that this 
should be the threshold used for claims of conﬁ  rmed association 
when the same SNP has been shown to be associated at genome-
wide signiﬁ  cance levels in another disease.  18   Power calculations 
were performed using the online genetic power calculator.  19   
  The primary analysis, from which conclusions regarding sup-
port for validation will be drawn, consisted of the joint analysis 
of both the UK and Ireland as a single population. As the differ-
ing population history could introduce bias due to population 
structure, we attempted to control this explicitly by analysing 
the UK and Ireland datasets separately followed by inverse-
  variance meta-analysis under the assumption of ﬁ  xed effects. 
Allelic heterogeneity between the two groups was estimated 
using the Cochran Q and I  2   statistics. 
  Exploratory analysis of subphenotypes were performed on 
the UK dataset based on the age at onset of psoriasis (type I 
psoriasis has an onset ≤40 years of age while type II psoriasis 
is deﬁ  ned as an onset >40 years of age) and seronegativity for 
rheumatoid factor (to exclude those patients who may have 
psoriasis and co-existent rheumatoid arthritis).     
  RESULTS 
  Genotyping 
  WTCCC2 control data were available for all SNPs except 
rs495337; this SNP was therefore genotyped in-house. All geno-
typed SNPs demonstrated good, well resolved clusters.   
  Statistical  analysis 
  Genotype frequencies for six SNPs conformed to Hardy–
Weinberg expectations, but rs610604 (  TNFAIP3  ) showed 
moderate deviation. SNPs mapping to the   IL23A   and   TNIP1   
genes showed conﬁ   rmed evidence for association with PsA 
at the stringent signiﬁ  cance values set (rs2066808, IL23A, OR 
0.54 (0.43–0.70), p = 9.1 x 10–7    ; rs17728338, TNIP1, OR 1.49 
(1.23–1.80); p = 3.5 x 10–5) (  table 1  ). No qualitative differences 
were noted when the UK and Ireland datasets were analysed 
separately for these two SNPs (supplementary tables 1 and 2, 
available online only). Meta-analysis of the two datasets sup-
port the results from the primary analysis, with only rs610604 
(  TNFAIP3  ) demonstrating signiﬁ  cant heterogeneity between the 
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two populations (supplementary table 3, available online only). 
The association of the   TNIP1   SNP, rs17728338, appeared stron-
ger in samples from PsA patients with type I psoriasis (n=478) 
with a much lower OR observed in the PsA samples with type 
II psoriasis (n=163) (OR 1.59 vs 1.12, respectively), although the 
CI overlap (  table 2  ). However, given the limited sample numbers 
these results should be considered with caution. There were no 
qualitative differences in the effects of any SNPs when the anal-
ysis was limited to seronegative individuals (n=302). 
  SNPs mapping to the   TNFAIP3  ,   TSC1   and   RNF114   genes 
showed borderline evidence for association at a nominal pvalue 
threshold of 0.05 and the remaining two SNPs showed no evi-
dence for association with PsA in this dataset (  table 1  ).     
  DISCUSSION 
  We have conﬁ  rmed that two loci,   IL23A   and   TNIP1  , associ-
ated with psoriasis in multiple populations, are also associated 
with PsA. Support for another three loci,   TNFAIP3  ,   TSC1   and 
  RNF114  , is provided by evidence of association at nominal 
p value thresholds of 0.05 although conﬁ  rmation of association 
with PsA will be required in other, large datasets. 
  SNPs mapping to the ﬁ  nal two loci tested,   SMARCA4   and 
  IL1RN  , did not show any evidence of association with PsA, 
which might indicate that they are exclusively associated with 
psoriasis. However, the power to detect association with these 
loci was poor in the sample size tested (20% and 17%, respec-
tively). Interestingly, the risk allele in both the psoriasis GWAS 
and the current data is the same and the strength and direction 
of association are similar. Association of   TSC1  ,   SMARCA4   and 
  IL1RN   with psoriasis was reported by Nair   et al  ,  12   although 
association was found in two datasets (p<0.05), the strength of 
association failed to reach genome-wide signiﬁ  cance levels in 
the combined dataset of nearly 13 000 samples. No other studies 
have yet replicated the association of   SMARCA4  , casting doubt 
on whether it truly represents a psoriasis susceptibility locus. 
However, an independent family-based study in a French popu-
lation has shown association of the   IL1RN   gene with psoriasis, 
albeit with a different SNP (rs315934; r  2   with rs397211=0.08).  20   It 
may be, therefore, that conﬁ  rmed evidence for association with 
PsA will be demonstrated in a larger dataset or by meta-analysis 
in the future. 
  Strengths of this study include the large sample size tested, 
the majority of whom were from the UK. Previous studies 
have shown minimal population stratiﬁ  cation across the UK 
thus minimising this potential source of bias in genotyping. 
Differences in genetic substructure between the UK and Irish 
population have been noted previously, but we controlled for 
this by analysing the data from each of the populations sepa-
rately followed by meta-analysis.  8   
  Some limitations of the study are apparent, particularly the 
lack of power to exclude association with PsA conﬁ  dently 
for psoriasis loci with small effect sizes. In addition, we have 
tested a single SNP at each locus based on previous reports of 
conﬁ  rmed association with psoriasis. However, this is unlikely 
to be the causal variant and association at any given locus may 
be complex. For example, several SNPs mapping to the   IL23R   
and   IL12B   genes show independent associations with psoria-
sis susceptibility; ﬁ  ne mapping of the associated regions will 
be required to identify all associated variants and to identify 
those most likely to be functionally important. A further limi-
tation is the fact that the psoriasis GWAS contain a large pro-
portion of patients with PsA, which makes comparison of the 
genetic aetiology of the two diseases very difﬁ  cult. Studies 
comparing the genetic aetiology of the two diseases would be 
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greatly facilitated by a psoriasis cohort reviewed by a rheu-
matologist to exclude patients with inﬂ  ammatory arthritis. It 
should also be noted that we have used a broad deﬁ  nition of 
PsA, including patients with psoriasis and a peripheral inﬂ  am-
matory arthritis, rather than the recently validated CASPAR 
criteria.  21   The latter include x-ray changes as part of the crite-
ria and this was not available for many subjects as cohort col-
lections were started before the introduction of these criteria. 
However, the majority of patients did satisfy these criteria, 
when x-ray data were available. Finally, a number of GWAS 
of psoriasis have been published recently in European and 
Asian populations providing a further opportunity to explore 
whether psoriasis susceptibility loci are also associated with 
PsA;  8     9     12     22     23   however, this information was not available at 
the time of study design and so the novel psoriasis loci identi-
ﬁ  ed from those scans still require investigation for association 
with PsA. 
  It is expected that epistasis between genetic loci may result 
in larger effect sizes. Indeed, the ﬁ  rst demonstration of this was 
recently reported in that association of  ERAP1   with psoriasis was 
only observed in individuals carrying the   HLA Cw*0602   allele.  8   
No interaction was detected between either of the   TNIP1   or 
  IL23A   markers and   HLA Cw*0602   (data not shown). However, 
interaction analyses would be best explored in larger sample col-
lections that would afford greater power than that provided in 
the current study. 
  In summary, our data largely support the thesis that psoria-
sis susceptibility loci are also associated with PsA; in particular, 
we show deﬁ  nite conﬁ  rmation that   IL23A   and   TNIP1   and sup-
portive evidence that the   TNFAIP3  ,   TSC1   and   RNF114   genes are 
associated with susceptibility to PsA as well as psoriasis.               
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